Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Phase 3
Recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Sermonix Pharmaceuticals Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT05696626
- Locations
- ๐จ๐ณ
The First Hospital of Lanzhou University, Lanzhou, China
๐จ๐ณLinyi Cancer Hospital, Linyi, China
๐จ๐ณThe First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Phase 2
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Sermonix Pharmaceuticals Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04432454
- Locations
- ๐บ๐ธ
Mary Crowley Cancer Research, Dallas, Texas, United States
๐บ๐ธYuma Regional Medical Center, Yuma, Arizona, United States
๐บ๐ธCompassionate Cancer Care Med Group - Clinic Aid USA - Fountain Valley, Fountain Valley, California, United States
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Phase 2
Active, not recruiting
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Sermonix Pharmaceuticals Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03781063
- Locations
- ๐บ๐ธ
Rocky Mountain Cancer Centers, Longmont, Colorado, United States
๐บ๐ธEmory University, Atlanta, Georgia, United States
๐บ๐ธThe Ohio State University - Comprehensive Cancer Center, Columbus, Ohio, United States